Funded Biotechnology Startups in Philadelphia
Philadelphia's biotechnology funding activity, across the 30 most recent rounds in this dataset, spans from a $200K angel investment by Hale Therapeutics i…
Philadelphia's biotechnology funding activity, across the 30 most recent rounds in this dataset, spans from a $200K angel investment by Hale Therapeutics in November 2021 to a $100M raise by Cabaletta Bio in June 2025. Therapeutics-focused companies dominate the roster — Fore Biotherapeutics closed a $75M Series D in August 2023, Vivodyne raised an unusually large $38M at the Seed stage in November 2023, and Century Therapeutics has appeared twice: a $160M Series C in March 2021 and a $60M follow-on in April 2024. Context Therapeutics reached $100M in May 2024.
A substantial share of rounds carry a "Series Unknown" classification rather than a named series, reflecting the disclosure norms common in mid-stage biotech. Non-dilutive capital is present but limited — Wistar Institute ($5M) and AUM LifeTech ($400K) each received grants in August 2022. Therapeutic modalities represented include gene therapy (iECURE, $50M Series A), RNA-targeting (Aro Biotherapeutics, $42M Series B), and cell-engineering platforms (Century Therapeutics).
Most recent rounds
30 shownRelated listings
Frequently asked
What are the largest disclosed rounds among Philadelphia biotech companies in this dataset?
Century Therapeutics leads with a $160M Series C closed in March 2021, followed by two $100M raises — Context Therapeutics (May 2024) and Cabaletta Bio (June 2025). Fore Biotherapeutics' $75M Series D (August 2023) and VintaBio's $64M round (April 2023) round out the top five by size among the 30 rows shown.
How many Philadelphia biotech rounds have closed in 2025 so far?
Four rounds appear in 2025 within this dataset: Cabaletta Bio ($100M, June), Vetigenics ($6M Seed, February), Arctic Therapeutics ($28M Series A, January), and Verismo Therapeutics ($4M Seed, January). That makes 2025 already notable for a nine-figure close alongside multiple early-stage raises.
Why do so many rounds show 'Series Unknown' instead of a named series?
Seventeen of the 30 rounds carry a Series Unknown classification, which typically reflects rounds where the company or investors did not publicly disclose the formal series designation. This pattern is common in mid-stage biotech raises, where bridge rounds, insider-led tranches, or structured deals may not map cleanly to a lettered series.
Are there any outsized early-stage raises in this segment?
Vivodyne closed a $38M Seed round in November 2023, well above typical Seed norms for biotech. iECURE's $50M Series A (September 2021) is similarly large for an early-stage raise. Both suggest institutional conviction at pre-clinical or early-clinical stages rather than lean proof-of-concept funding.
Does the dataset include any non-dilutive funding?
Two grant-type rounds appear: Wistar Institute received $5M in August 2022, and AUM LifeTech received $400K in the same month. These are the only non-dilutive rounds visible across the 30 rows shown.
Which companies have raised multiple rounds visible in this dataset?
Century Therapeutics appears twice — a $160M Series C in March 2021 and a $60M Series Unknown in April 2024 — making it the only company with more than one round among the 30 rows shown. The repeat appearance signals ongoing capital needs consistent with late-stage clinical development.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.